United States Food and Drug Administration (USFDA) has concluded audit at Jubilant Pharmova’s wholly-owned subsidiary -- Jubilant Pharma’s subsidiary -- Jubilant Generics’ solid dosage formulations facility on February 2, 2024 at Roorkee site, India. The USFDA has issued 4 observations pursuant to the completion of audit. The company will submit an action plan on the observations.
The company currently supplies only one product to US from Roorkee facility, that contributed less than one percent of Jubilant Pharmova’s 9M’FY24 revenues.
Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: